Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.42 |
| ▸ | SRC | P12931 | 1/20 | 0.36 |
| ▸ | AXL | P30530 | 2/20 | 0.33 |
| ▸ | TYRO3 | Q06418 | 2/20 | 0.33 |
| ▸ | MERTK | Q12866 | 2/20 | 0.33 |
| ▸ | CFTR | P13569 | 1/20 | 0.33 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.33 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.32 |
| ▸ | IGF1R | P08069 | 1/20 | 0.32 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.32 |
| ▸ | AKT1 | P31749 | 1/20 | 0.32 |
| ▸ | AKT2 | P31751 | 1/20 | 0.32 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.31 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.31 |
| ▸ | FGFR3 | P22607 | 2/20 | 0.31 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5148959 | 0.87 | HRH3 (0.41) | HRH3AKT1AKT2 | |
| SCHEMBL5149127 | 0.86 | ROCK1 (0.43) | HRH3 | |
| SCHEMBL6134849 | 0.84 | HRH3 (0.42) | HRH3SRC | |
| SCHEMBL5150959 | 0.84 | FGFR1 (0.39) | SRCTP53FGFR1FGFR2FGFR3 | |
| SCHEMBL5149214 | 0.83 | MCHR1 (0.41) | HRH3AKT1AKT2 | |
| SCHEMBL5149050 | 0.83 | FGFR1 (0.36) | HRH3SRCTP53FGFR1FGFR2 | |
| SCHEMBL6133963 | 0.81 | HRH3 (0.44) | HRH3SRC | |
| SCHEMBL5147909 | 0.81 | KMT2A (0.39) | TP53 | |
| SCHEMBL5147958 | 0.80 | ADORA2A (0.39) | SRCTP53FGFR1FGFR2FGFR3 | |
| SCHEMBL5149200 | 0.79 | SRC (0.43) | SRCIGF1RFGFR1FGFR2FGFR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7265120-B2 | Pyrazine derivatives and pharmaceutical use thereof | ASTELLAS PHARMA INC. (JP) | 2007-09-04 | — | — | US | disclosed |
| CN-1938296-A | Pyrazine derivatives and pharmaceutical use thereof as adenosine antagonists | ASTELLAS PHARMA INC (JP) | 2007-03-28 | — | — | CN | disclosed |
| US-20050222159-A1 | Pyrazine derivatives and pharmaceutical use thereof | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2005-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222159-A1 | Pyrazine derivatives and pharmaceutical use thereof | ADORA2A, HTR5A, ADORA1 | HRH3 43/4885SRC 1884/4885AXL 3325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.